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Background: The evidences of therapy with drug-eluting stents (DES) in ST-elevation myocardial infarction are mostly based on trials performed 
with first-generation DES. There is paucity of data with long-term follow up with second-generation DES in this setting.
Methods: The ESTROFA-MI is a multicenter retrospective registry collecting consecutive patients treated in a primary angioplasty procedure with a 
first-generation DES (paclitaxel-eluting stent, PES) and with a second-generation DES (everolimus-eluting stent, EES).
Results: The registry is still open and 15 centers have provided data so far. Up to now 521 pts have been included, 264 treated with PES and 
257 treated with EES. The clinical and angiographic characteristics were comparable in both groups without significant differences but with a trend 
for more diabetes in EES group (26.1% vs 33.8%:p=0.06). The 2 years survival free of death and infarction was 89.2% for PES and 95.8% for EES 
(p=0.008). Definite or probable thrombosis was 3.1% for PES and 0.7% for EES (p=0.09). At 2 years the incidence of target lesion revascularization 
was 4.5% for PES and 1.8% for EES (p=0.1). 
Conclusions: The results of this multicenter registry suggest a higher safety and efficacy profile for Xience at 2 years in primary angioplasty. 
However additional enrollment and multivariant adjustment-propensity score matching are required and will be performed prior to make definite 
conclusions.
